@article{7a76721690384f19b68fca25c32912f2,
title = "University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL",
keywords = "MEK inhibition, novel therapies, relapsed/refractory DLBCL, selumetinib",
author = "Natalie Galanina and Smith, {Sonali M.} and Chuanhong Liao and Adam Petrich and Bernadette Libao and Ronald Gartenhaus and Westin, {Jason R.} and Cohen, {Kenneth S.} and Knost, {James A.} and Stadler, {Walter M.} and Austin Doyle and Theodore Karrison and Gordon, {Leo I.} and Evens, {Andrew M.}",
note = "Funding Information: This study was sponsored by the NCI. In addition, the authors declare no conflicts of interest. Funding Information: Supported by NCI contract N01-CM-2011-00071C.",
year = "2018",
month = apr,
doi = "10.1111/bjh.14544",
language = "English (US)",
volume = "181",
pages = "264--267",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",
}